Clinical, laboratory and echocardiographic parameters suggestive of multi-system inflammatory syndrome in children at a tertiary hospital in South Africa
Article Sidebar
Main Article Content
Abstract
Background. Worldwide studies have described features and outcomes of multi‐system inflammatory syndrome in children (MIS‐C) to assist with the diagnosis and guide medical management, with few studies emanating from Africa.
Objective. To describe the clinical, laboratory and echocardiographic parameters suggestive of MIS‐C.
Methods. The paediatric cardiology database identified all patients referred with suspected MIS‐C at Chris Hani Baragwanath Academic Hospital (CHBAH), from 1 March 2020 until 31 December 2021. Patients were classified as ‘MIS‐C likely’ or ‘MIS‐C unlikely’ based on the 2020 Centers for Disease Control and Prevention (CDC) criteria for MIS‐C.
Results. A total of 101 patients were analysed, with 60 in the ‘MIS‐C likely’ group and 41 patients in the ‘MIS‐C unlikely’ group. The significant clinical features differentiating between the ‘MIS‐C likely’ and the ‘MIS‐C unlikely’ groups were the presence of documented fever (p=0.018) and eye changes (p<0.001). Patients with a positive COVID antibody test that were referred for suspected MIS‐C were most likely to present with MIS‐C (p< 0.001). Laboratory parameters suggesting a greater likelihood of patients having MIS‐C was a high troponin T (p=0.018) and a high C‐reactive protein (CRP) (p=0.019). The main echocardiographic feature associated with a MIS‐C diagnosis was left ventricular (LV) dysfunction at presentation (p=0.023). In the adjusted logistic regression analyses, the contributory findings associated with a greater risk of having MIS‐C were fever and LV dysfunction (OR 6.52 (95% CI 2.31 ‐ 18.45); p<0.001 and 6.70 (95% confidence interval (CI) 1.61 ‐ 28.59); p =0.009, respectively).
Conclusion. Clinical features such as documented fever and eye changes together with a positive COVID antibody test suggest that patients had MIS‐C in our setting. Laboratory findings of elevated CRP and troponin T in patients with suspected MIS‐C assisted with the diagnosis. Patients with suspected MIS‐C with LV dysfunction at presentation were more likely to have MIS‐C.
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The SAJCH is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
How to Cite
References
1. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID‐19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020;24:91‐98. https://doi.org/10.1016/j.jare.2020.03.005
2. World Health Organization. WHO Director‐General’s Opening Remarks at the Media Briefing on COVID‐19 – 11 March 2020. Geneva: WHO, 2020. https://www.who.int/director‐general/speeches/detail/who‐director‐general‐ s‐opening‐remarks‐at‐the‐media‐briefing‐on‐COVID‐19‐‐‐11‐march‐2020 (accessed 27 November 2023).
3. Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. Lancet 2017;390(10098):946‐958. https://doi.org/10.1016/s0140‐ 6736(17)30938‐8
4. Otto WR, Geoghegan S, Posch LC, et al. The epidemiology of severe acute respiratory syndrome Coronavirus 2 in a pediatric healthcare network in the United States. J Pediatric Infect Dis Soc 2020;9(5):523‐529. https://doi. org/10.1093/jpids/piaa074
5. Pierce CA, Preston‐Hurlburt P, Dai Y, et al. Immune responses to SARS‐ CoV‐2 infection in hospitalised pediatric and adult patients. Sci Transl Med 2020;12(564):eabd5487. https://doi.org/10.1126/scitranslmed.abd5487
6. Viner RM, Whittaker E. Kawasaki‐like disease: Emerging complication during the COVID‐19 pandemic. Lancet 2020;395(10239):1741‐1743. https://doi. org/10.1016/S0140‐6736(20)31129‐6
7. Riphagen S, Gomez X, Gonzalez‐Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID‐19 pandemic. Lancet 2020;395(10237):1607‐1608. https://doi.org/10.1016/s0140‐6736(20)31094‐1
8. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki‐like disease at the Italian epicentre of the SARS‐CoV‐2 epidemic: An observational cohort study. Lancet 2020;395(10239):1771‐1778. https://doi.org/10.1016/ S0140‐6736(20)31103‐X
9. Webb K, Abraham DR, Faleye A, McCulloch M, Rabie H, Scott C. Multisystem inflammatory syndrome in children in South Africa. Lancet Child Adolesc Health 2020;4(10):e38. https://doi.org/10.1016/S2352‐4642(20)30272‐8
10. Malik P, Patel U, Mehta D, et al. Biomarkers and outcomes of COVID‐19 hospitalisations: Systematic review and meta‐analysis. BMJ Evid Based Med 2021;26(3):107‐108. https://doi.org/10.1136/bmjebm‐2020‐111536
11. Belhadjer Z, Méot M, Bajolle F, et al. Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS‐CoV‐2 pandemic. Circulation 2020;142(5):429‐436. https://doi.org/10.1161/ CIRCULATIONAHA.120.048360
12. Balasubramanian S, Sankar J, Dhanalakshmi K, et al. Differentiating multisystem inflammatory syndrome in children (MIS‐C) and its mimics – a single‐center experience from a tropical setting. Indian Pediatr 2023;60(5):377‐380.
13. Abdelaziz TA, Abdulrahman DA, Baz EG, et al. Clinical and laboratory characteristics of multisystem inflammatory syndrome in children associated with COVID‐19 in Egypt: A tertiary care hospital experience. J Paediatr Child Health 2023;59(3):445‐452. https://doi.org/10.1111/jpc.16311
14. Migowa A, Samia P, Del Rossi S, et al. Management of Multisystem Inflammatory Syndrome in Children (MIS‐C) in resource‐limited settings: The Kenyan experience. Pediatr Rheumatol Online J 2022;20(1):110. https:// doi.org/10.1186/s12969‐022‐00773‐9
15. Chinniah K, Bhimma R, Naidoo KL, et al. Multisystem inflammatory syndrome in children associated with SARS‐CoV‐2 infection in KwaZulu‐Natal, South Africa. Pediatr Infect Dis J 2023;42(1):e9‐14. https://doi.org/10.1097/ INF.0000000000003759
16. Butters C, Abraham DR, Stander R, et al. The clinical features and estimated incidence of MIS‐C in Cape Town, South Africa. BMC Pediatr 2022;22(1):241. https://doi.org/10.1186/s12887‐022‐03308‐z.
17. Centers for Disease Control and Prevention. Information for Healthcare providers about Multisystem Inflammatory Syndrome in Children (MIS‐C). Atlanta: CDC, 2023. https://www.cdc.gov/mis/mis‐c/hcp/index.html (accessed 6 August 2023).
18. Dallaire F, Dahdah N. New equations and a critical appraisal of coronary artery Z scores in healthy children. J Am Soc Echocardiogr. 2011 Jan;24(1):60‐74. https://doi..org.10.1016/j.echo.2010.10.004
19. Yasuhara J, Kuno T, Takagi H, Sumitomo N. Clinical characteristics of COVID‐19 in children: A systematic review. Pediatr Pulmonol 2020;55(10):2565‐2575. https://doi.org/10.1002/ppul.24991
20. Radia T, Williams N, Agrawal P, et al. Multi‐system inflammatory syndrome in children and adolescents (MIS‐C): A systematic review of clinical features and presentation. Paediatr Respir Rev 2021;38:51‐57. https://doi.org/10.1016/j. prrv.2020.08.001
21. García‐Salido A, de Carlos Vicente JC, Belda Hofheinz S, et al. Severe manifestations of SARS‐CoV‐2 in children and adolescents: From COVID‐19 pneumonia to multisystem inflammatory syndrome. A multicentre study in pediatric intensive care units in Spain. Crit Care 2020;24(1):666. https://doi. org/10.1186/s13054‐020‐03332‐4
22. Yilmaz Ciftdogan D, Ekemen Keles Y, Cetin BS, et al. COVID‐19‐associated multisystemic inflammatory syndrome in 614 children with and without overlap with Kawasaki disease‐Turk MIS‐C study group. Eur J Pediatr 2022;181(5):2031‐2043. https://doi.org/10.1007/s00431‐022‐04390‐2
23. Kaushik A, Gupta S, Sood M, Sharma S, Verma S. A systematic review of multisystem inflammatory syndrome in children associated with SARS‐CoV‐2 infection. Pediatr Infect Dis J 2020;39(11):e340‐346. https://doi.org/10.1097/ INF.0000000000002888
24. Khalid A, Patel N, Yusuf Ally Z, Ehsan S. Incidental finding of coronary artery dilatation in children with history of COVID‐19 having minimal or no symptoms: Raising red flag. Cureus 2022;14(4):e24348. https://doi. org/10.7759/cureus.24348
25. Kawsara A, Núñez Gil IJ, Alqahtani F, Moreland J, Rihal CS, Alkhouli M. Management of coronary artery aneurysms. JACC Cardiovasc Interv 2018;11(13):1211‐1223. https://doi.org/10.1016/j.jcin.2018.02.041
26. Reyna J, Reyes LM, Reyes L, et al. Coronary artery dilation in children with febrile exanthematous illness without criteria for Kawasaki Disease. Arq Bras Cardiol 2019;113(6):1114‐1118. https://doi.org/10.5935/abc.20190191